1. Basic information of the company:
The company's turnover in 2013 was about RMB 612 million, which was about 15.31% higher than that of RMB 530 million in the same period last year. The company has Haiwang Fuyao, Jiangsu Haiwang, Haiwang Changjian and other subsidiaries. The main source of income is Haiwangfu medicine, and its main varieties are large infusion, tumor drugs and basic drugs.
2. Tijiao tablets have definite curative effect.
Tegio is an oral anticancer agent of fluorouracil derivatives, which includes tegafur, gem and otelaxi. It is the only compound oral preparation that simulates the effect of intravenous drip. At present, the indication of Tijiao tablets is for advanced or metastatic gastric cancer.
3. To enter the bidding catalogue of some provinces for Geo tablets:
Tijiao tablets have the fastest growth rate among tumor drugs, and the current market size is estimated to be 2 billion according to the sample hospital. Tigio is currently in the category B health insurance catalogue, and there are 4 enterprises currently producing. Their respective shares in 2012 are: Hengrui Pharmaceutical 18.5%, Qilu Pharmaceutical 9.92%, Dapeng Pharmaceutical 15.4%, Shandong New era 60% (first imitation). At present, the market is only capsule dosage form, the company's Tijiao tablet is the only dosage form, bidding as a separate bid, has obvious advantages. Giorgio tablets are listed in the tender catalogue in some provinces.
4. Tijiao tablet sales strategy:
Tijiao tablet sales plan is carried out through the combination of its own team and distributors, through its own team in the areas where the group has advantages, and through professional dealers in other areas. This year is the year of bidding, with the help of a favorable opportunity to complete the provincial bid, and the volume is expected to be released next year.
5. POCT technology is leading, and its advantages are obvious:
With the advantages of fast and simple, POCT has been growing rapidly, and the domestic industry is growing at a rate of 30%, with a small gap at home and abroad. POCT has three generations of products: the first generation, qualitative, the second generation: semi-quantitative, and the third generation: fluorescence quantitative. The company uses quantum dots as high-efficiency fluorescent probes, and its competitive advantage is very obvious. The division of diagnostic reagents is as follows: Jiangsu Haiwang-quantitative production, Taizhou Haiwang R & D-pilot test.
6. diagnostic reagents have a wide range of uses:
Diagnostic reagents have a wide range of uses, such as rapid diagnosis of clinical diseases and detection of food safety such as clenbuterol. Clinical registration: high-sensitivity c-reactive protein detection kit, calcitonin original quantitative detection kit, entered the clinic this year, is expected to be on the market next year. Food safety testing is expected to be available this year.
7. Research progress of recombinant human thymosin α 1 for injection.
The clinical trial of thymosin α 1 is being carried out in an orderly manner as planned, and the phase Ⅰ clinical trial was completed in December 2012. the results of the phase Ⅰ clinical trial showed that recombinant human thymosin α 1 for injection was safe under the conditions specified in the clinical regimen. The phase Ⅱ clinical trial has been successfully started and completed. The indication of the clinical trial is chronic hepatitis B.
8. Summary and suggestions:
The company's current business operation is sound, the new product has a very obvious competitive advantage, Tijiao tablet is the only dosage form, bidding as a separate bid, has obvious advantages. POCT diagnostic reagent technology has obvious advantages and broad application prospects, so it is suggested to actively follow and pay attention to the company.